

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2020

		Quarter ended			Year ended Year ende	
Sr. No.	. Particulars			31-03-2019	31-03-2020	31-03-2019
		(Audited)	(Un-audited)	(Audited)	(Audited)	(Audited)
1	Revenue from Operations	1397 80	1315 91	1368 87	5561 43	5605 4
II	Other Income	8 5 5	015	1 52	9 26	21
111	Total Revenue (I + II)	1406.35	1316.06	1370.39	5570.69	5607 5
IV	Expenses	2100.00	1020.00			
	(a) Cost of Material Consumed	674 50	562 02	755 72	2455 26	2448.4
	(b) Purchase of Stock-in-Trade	8 22	302 02	0.00	37 02	3.4
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	154 26	(132.04)	40 10	(63 32)	516
	(d) Employee Benefits Expenses	299 34	277 03	226 69	1067 37	946 9
	(e) Finance Cost	133 21	26 61	51 78	218 32	174 6
	(f) Depreciation and Amortisation Expenses	103.75	19 35	19 45	155 39	69 4
	(g) Other Expenses	7.08	504.42	167 61	1485 15	1628 7
	Total Expenses (IV)	1380.36	1257.39	1261.35	5355.19	5323.3
٧	Profit / (Loss) before Exceptional items and Tax (III - IV)	25.99	58 67	109 04	215 50	284 1
VI	Exceptional Items	2000	3007	100 04		
VII	Profit / (Loss) Before Tax (V - VI)	25 99	58 67	109 04	215 50	284 1
VIII	Tax Expense	20 00	30 07	100 04	210 00	
410	(1) Current Tax	23 88	15 67	33 82	71 58	82 5
	(2) Deferred tax	2000	1007	-	14 33	000
_		23.88	15.67	33.82	85.91	82 5
10	Total Tax Expenses	23.88	43 00	75.22	129 59	2016
IX	Profit / (Loss) for the period from Continuing Operations (VII -VIII)	2.11	43 00	73.22	120 00	2010
X	Profit / (Loss) from Discontinued Operations	-				
XI	Tax expenses of Discontinued Operations					
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	2.11	43 00	75 22	129 59	201 6
XIII	Profit / (Loss) for the period (IX+XII)	2.11	43.00	75.22	123 33	2010
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-				
	(ii) Income tax relating to items that will not be reclassified to profit or loss					
	B (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss		•	-		
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	2 11	43 00	75 22	129 59	201 6
XIV	Details of Equity share capital					
	Paid up Equity capital (Face Value of Rs 10/- each)	364 83	364 83	364 83	364 83	364 8
	Face value of Equity Share Capital	10 00	10 00	10 00	10 00	100
XVI	Earnings Per Equity Share (for Continuing operation):					
	(a) Basic	0 06	1 18	2 06	3 55	5 5
	(b) Diluted	0.06	1 18	2.06	3 55	5.5
XVII	Earnings Per equity share (for Discontinued operation)					
	(a) Basic	17	-	+		
	(b) Diluted					
XVIII	Earnings Per Equity Share (for Discontinued & Continuing operation)					
	(a) Basic	0 06	1 18	2 06	3 55	5.5
	(b) Diluted The Land of the Control	0 06	1 18	2 06	3 55	5.5







Statement of Assets and Liabilities

Rs. In Lakhs

	Particulars	As at March 31, 2020	As at March 31, 2019
1	ASSETS		
1)	Non-current assets		
	a) Property, Plant and Equipment	1043 15	406 92
	b) Capital work-in-progress	22 23	22 23
	c) Other Intangible assets	0 98	1 53
	d) Financial assets		
	(i) Loans		
	(ii) Other financial assets	30.90	20 82
	e) Deferred tax assets (net)		
	f) Income-tax assets (net)	17.78	5 40
	g) Other non-current assets		
	Total Non-current assets (1)	1115.02	456.90
2)	Current assets		
	a) Inventories	3219 84	2982 13
	b) Financial assets		
	(i) Trade receivables	2335 31	2070 47
	(ii) Cash and cash equivalents	72 29	32 62
	(iii) Bank balances other than (ii) above		
	(iv) Loans		
	(v) Other current financial assets	0 93	1 64
	c) Other current assets	138 25	132 39
	Total Current assets (2)	5766.62	5219.25
	TOTAL ASSETS (I = 1 + 2)	6881.63	5676.15
II	EQUITY & LIABILITIES		
1)	Equity		
	a) Equity Share capital	542 43	542 43
	b) Other Equity	2318 49	2263 20
	Total Equity (1)	2860.92	2805.63
2)	Liabilities		
	Non-current liabilities		
	a) Financial Liabilities		
	(i) Other financial liabilities	957.31	276 5
	b) Long-term provisions	(19.56)	(16 82
	c) Deferred tax liabilities (net)	14 33	
	Total Non-current liabilities	952.09	259.6
	Current liabilities		
	a) Financial Liabilities		
	(i) Trade payables	1251 23	825 1
	(ii) Other current financial liabilities	1821 58	1760 3
	b) Other current liabilities	(4 20)	25 3
	c) Short-term provisions	-	
	Total Current liabilities	3068.62	2610.8
	Total Liabilities (2)	4020.70	2870.5
	TOTAL EQUITY AND LIABILITIES (II = 1 + 2)	6881.63	5676.15










Cash Flow Statement for the Quarter and Year ended March 31, 2020

Rs. In Lakhs

	RS. In L		
Particulars	As at March 31, 2020	As at March 31, 2019	
A. Cash flow from operating activities	Maicii 31, 2020	March 31, 2013	
Net Profit before tax	215.50	284 18	
Adjustments for :	213.30	204.10	
Depreciation and amortisation expense	155 39	69 43	
Interest income	(167)	(2 09)	
Reclassification on account of adoption of Ind AS 116	(39 57)	(2007)	
Profit on redemption of mutual funds (net)	(55.57)		
Exchange gain	6 63	(10 80)	
Provision for Leave encashment	-	(10 00)	
Provision for Gratuity	19 56	16 82	
Sundry balances written back/written-off	1000		
Operating profit before working capital changes	355.84	357.54	
Adjustments for :	333.54	007101	
Decrease / (Increase) in inventories	(237.71)	75 16	
Decrease / (Increase) in trade receivable	(264 83)	(260 75)	
Decrease / (Increase) in financials and non-financial assets	(21.74)	(20 94)	
Decrease / (Increase) in other assets and receivables	(5.86)	14 61	
(Decrease) /Increase in trade and other payables	468 07	71 63	
Cash generated from operations	293.77	237.26	
income tax refund / (paid)	(85.91)	(82 54)	
Net cash (used in) / generated from operating activities	207.86	154.71	
B. Cash flow from investing activities			
Acquisition of fixed assets and capital work in progress	(107.93)	(98 20)	
Proceeds from sale of investments	164	-	
Interest income on fixed deposits and other advances	(24 53)	(3 93)	
Net cash (used in) / generated from investing activities	(130.81)	(102.13)	
C. Cash flow from financing activities	` 1	` ` `	
Proceeds from issuance of Debentures		-	
Proceeds from Short term borrowings	(37 38)	(127 19)	
Net cash (used in) / generated from financing activities	(37.38)	(127.19)	
Net (decrease) / increase in cash and cash equivalents (A+B+C)	39.66	(74.61)	
Cash and cash equivalents as at the beginning of year	32 62	107 23	
Cash and cash equivalents as at the end of year	72.29	32.62	
Components of cash and cash equivalents (Also, refer note 10)	72.20	02.02	
Cash in hand	2 27	6 5 3	
Balance with scheduled banks in current accounts	70 02	26 09	
	72.29	32.62	
Total	72.23	32.02	





Notes:

- 1). The above Financial Results were reviewed by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on June 30, 2020.
- The Company has one reportable business segment "Medical Devices".
- In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out audit of the Standalone Audited Financial Results for the Quarter and Year ended March 31, 2020
- Impact of COVID-19 Pandemic

The COVID-19 outbreak has spread rapidly during the last quarter of the financial year. Governments across the globe, including in India, have undertaken various measures to contain the spread of this virus including restrictions on travel, social distancing, and other emergency measures. These measures have had a direct impact on our business and have affected the supply chains and production of our medical devices. Lower economic activity has also resulted in the supressed demand for our medical devices. Our Company initially experienced some delays in delivery of supplies to hospitals and nursing homes due to restrictions on courier services, but this has gradually stabilized and deliveries are now regular and timely. In view of the lockdown and curfew announced across many states in India, the Company has undertaken and strengthened various measures to ensure the safety and well-being of its employees and has focused on continued delivery of devices across the country, by ensuring that its key functions i.e. procurement, manufacturing, supply chain, marketing, sales and support functions continue to operate smoothly. Management has considered its liquidity position as at March 31, 2020 and over the next twelve months from the date of approval of these financial statements, and has concluded that the Company may face liquidity in the course of business.

The management has carried out a physical verification of inventories at all locations to obtain comfort over the existence and condition of inventories as at March 31, 2020. Due to the current COVID-19 pandemic situation, the Company has implemented strict safety measures at the manufacturing plant, to ensure there is minimal risk of contamination and one such measure relates restriction of entry inside the plant only to those employees who are related with the manufacturing activity. As explained above, management has considered all possible impacts of known events arising from COVID-19 pandemic in the preparation of these financial statements and therefore, believes that the current pandemic is likely to have a material impact on the operations and financial position of the Company. However, the impact assessment of COVID-19 is a continuous process given the uncertainties associated with its nature and duration. The Company will continue to closely monitor any material changes to future economic conditions

- The figures for the Quarter ended March 31, 2020 and March 31 2019 are the balancing figures between the audited figures in respect of the full financial year and published unaudited year to date figures upto the third quarter of the respective financial year which were subjected to review by the Statutory Auditors.
- Previous figures have been regrouped/reclassified, wherever necessary, to confirm with the current period's presentation for the purpose of comparability.
- The audited financial results for the Quarter and Year ended March 31, 2020 are available on the website of BSE LTD at www bseindia.com and on Company's website at www.centenialindia.com

CENTENIAL SURGICAL SUTURE LTD. Wijay MAJREKAR Managing Director & Chief Executive Officer DIN: 00804808 Date : June 30, 2020

Place Mumbai, Maharashtra